Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Long-term Safety Trial With NVDX3
- Conditions
- Distal Radius FracturesDegenerative Lumbar Spondylolisthesis
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novadip Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT06532253
- Locations
- 🇱🇺
Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
Prospective Study in Adults Evaluating Safety & Efficacy of NVD003 for Bone Reconstruction to Treat Lower Limb Nonunion
- Conditions
- Recalcitrant Lower Limb Nonunion
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Novadip Biosciences
- Target Recruit Count
- 11
- Registration Number
- NCT06335394
- Locations
- 🇧🇪
Centre Hospitalier Interregional Edith Cavel (CHIREC) - Clinique Ste Anne-St Remi, Anderlecht, Belgium
🇧🇪Algemeen Ziekenhuis (AZ) Sint-Jan Brugge - Oostende AV - Campus Sint-Jan, Brugge, Belgium
🇧🇪Centre Hospitalier Universitaire CHU/UVC Brugmann (Site Horta), Brussel, Belgium
Proof-of-concept Study with NVDX3 for Treatment of Distal Radius Fractures.
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Novadip Biosciences
- Target Recruit Count
- 10
- Registration Number
- NCT05987033
- Locations
- 🇱🇺
Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis
- Conditions
- Degenerative Lumbar Spondylolisthesis
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Novadip Biosciences
- Target Recruit Count
- 5
- Registration Number
- NCT05961956
- Locations
- 🇱🇺
Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia
- Conditions
- Congenital Pseudarthrosis of Tibia
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Novadip Biosciences
- Target Recruit Count
- 4
- Registration Number
- NCT05693558
- Locations
- 🇺🇸
Adult/Pediatric Limb Lengthening and Reconstruction - International Center for Limb Lengthening - Rubin Institute for Advanced Orthopedics Baltimore, Baltimore, Maryland, United States
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
- Prev
- 1
- 2
- Next
News
Novadip Receives FDA RMAT Designation for NVD003 Regenerative Therapy in Rare Pediatric Bone Disease
Novadip Biosciences received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for NVD003, an autologous stem cell therapy for congenital pseudarthosis of the tibia (CPT).
Novadip's Novel Bone Graft Material Achieves 100% Fracture Union Rate in Phase Ib/IIa Trial
Novadip Biosciences' NVDX3, an allogeneic bone grafting material derived from stem cells, demonstrated complete bone fracture union in all patients during a 12-month Phase Ib/IIa trial.